A phase III RCT compared gefitinib and erlotinib treatment in EGFR mutation–positive NSCLC and found significantly higher RR and longer median OS for patients with EGFR exon 19 mutations than for patients with EGFR exon 21 mutations following erlotinib or gefitinib treatment. Here, EGFR is linked to non-small cell lung carcinoma.